As per MRFR analysis, the China Patient-Derived Xenograft Model Market Size was estimated at 19.77 (USD Million) in 2024.The China Patient-Derived Xenograft Model Market Industry is expected to grow from 22.4(USD Million) in 2025 to 87.24 (USD Million) by 2035.
The China Patient-Derived Xenograft Model Market CAGR (growth rate) is expected to be around 13.156% during the forecast period (2025 - 2035).
The China Patient-Derived Xenograft (PDX) Model Market is experiencing significant growth driven by advancements in precision medicine and increased investment in oncology research. The demand for personalized therapeutic solutions is pushing the need for reliable preclinical models that can mimic human tumor biology closely, resulting in an uptick in the use of PDX models in the country's pharmaceutical and biotechnology sectors.
The Chinese government is supporting this trend through initiatives aimed at boosting innovation in healthcare, thereby enhancing research capabilities in medical institutions and universities across the nation. Opportunities in the China PDX model market are expanding as more local research centers and biopharmaceutical companies seek to collaborate with international entities in the development of innovative cancer treatment options.
Greater access to funding, as evidenced by various government grants and incentives for biomedical research, is encouraging startups and established companies alike to invest in developing advanced PDX models that cater to specific patient genetics, particularly in areas suffering from high cancer prevalence. In recent times, there has been a noticeable trend toward enhancing the capabilities of PDX models with the integration of advanced technologies such as 3D bioprinting, artificial intelligence, and genomic sequencing.
These technologies offer the potential for improved model accuracy and efficacy, which is critical for the development of targeted therapies.Moreover, as regulatory frameworks in China become more conducive to research and testing, there is a growing momentum in the market that signals a shift towards more sophisticated and adaptable patient-derived models, leading to better research outcomes and faster drug development timelines. This convergence of factors establishes China as a burgeoning hub for innovative cancer research using PDX models.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The rise in cancer cases in China is a significant driver for the China Patient-Derived Xenograft Model Market Industry. Data shows that the number of new cancer cases in China has risen sharply over the past decade, with the National Cancer Center of China reporting an increase of approximately 10% in new cases annually. In 2020, there were about 4.57 million new cancer cases diagnosed, leading to an urgent need for advanced research models like patient-derived xenografts for effective treatment strategies.
In addition, factors such as an older population and environmental concerns are increasing the rate of cancer diagnosis, which has created a greater need for advanced research and development options in this field. The Chinese Society of Clinical Oncology, for example, pushes for more funding for cancer research and other related projects, highlighting the role of patient-derived xenograft models in personalized medicine.
The Chinese government has been making substantial investments in healthcare research and development, including cancer research initiatives. Recent policies such as the 'Healthy China 2030' initiative aim to enhance healthcare services and innovation in medical technology. The government has allocated funds to support domestic biotechnology firms and research institutions involved in developing patient-derived xenograft models. The Ministry of Science and Technology of the People's Republic of China has launched several funding programs to encourage research in this direction.
As a result, increased availability of funds and resources is expected to accelerate advancements in patient-derived xenograft technology, thereby boosting the market growth in this industry.
There is a notable shift towards personalized medicine in China, where treatments are customized based on individual patient characteristics. This trend is being driven by the increasing recognition of the limitations of traditional one-size-fits-all therapies. Patient-derived xenograft models are pivotal in this context, enabling researchers and pharmaceutical companies to test drug responses on human-derived tumor models, ultimately improving treatment efficacy.
Institutions like Peking University and Shanghai Jiao Tong University are conducting studies to explore the application of patient-derived xenografts in personalized therapy. With the growing focus on precision medicine, the adoption of these models is expected to rise significantly in China's healthcare landscape.
The China Patient-Derived Xenograft Model Market within the Tumor Type segment showcases a dynamic landscape characterized by distinct categories, including Lung Cancer, Pancreatic Cancer, Prostate Cancer, Breast Cancer, and Other Cancer types. This market segment is particularly significant given the rising incidence of various cancer types in China, driven by factors such as lifestyle changes, aging populations, and environmental influences.
Lung Cancer, as one of the leading causes of cancer-related mortality, contributes substantially to the demand for Patient-Derived Xenograft models, which facilitate groundbreaking Research and Development efforts aimed at better understanding the disease and developing targeted therapies.Prostate Cancer holds a noteworthy position in this segment as well, primarily due to the increasing awareness of men's health issues and the growing prevalence of the disease among aged populations.
Similarly, Breast Cancer remains a critical focus, with substantial research efforts being directed towards innovative treatment protocols that require precise modeling of cancerous tissues. The importance of Pancreatic Cancer cannot be overlooked, given its notoriously aggressive nature and the challenges associated with early detection. This makes Patient-Derived Xenograft models invaluable for researchers striving to uncover novel therapeutic strategies.
The Other Cancer’ category encompasses a wide array of malignancies, reflecting the diverse nature of cancer and the need for tailored treatment approaches. Each of these cancer types presents unique challenges and opportunities in the realm of cancer research; consequently, the China Patient-Derived Xenograft Model Market segmentation by Tumor Type is vital for advancing therapies and improving patient outcomes.
The growing investment in cancer research and supportive government policies further catalyze the opportunities in this sector, ensuring that the market remains pivotal in the broader context of global oncology advancements. Overall, the Tumor Type segmentation within the China Patient-Derived Xenograft Model Market plays a crucial role in facilitating targeted cancer therapies, addressing a wide spectrum of oncological needs in the region.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The China Patient-Derived Xenograft Model Market is characterized by its division into various model types, notably including Mice and Rats. These model types play a crucial role in preclinical research and drug development processes, as they closely mimic human physiological responses and disease conditions. Mice models, for instance, are predominantly used due to their genetic similarities to humans and their well-established genetic framework, making them invaluable in oncology and immunology studies.
Conversely, Rats offer distinct advantages in pharmacokinetic studies and behavioral research, largely owing to their larger size and more complex behavioral patterns.This segmentation reflects the growing emphasis on personalized medicine and targeted therapies within China's robust pharmaceutical landscape. The increasing investments by research institutions and biotech firms into developing advanced xenograft models further illustrate the market's expansion potential.
As the demand for personalized medicine continues to rise, both Mice and Rats are set to amplify their significance in bridging the translational gap between laboratory findings and clinical outcomes in China, thereby driving innovation in the healthcare sector.
The End-User segment of the China Patient-Derived Xenograft Model Market is composed of several key players, notably Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Contract Research Organizations (CROs), and Contract Development and Manufacturing Organizations (CDMOs). Pharmaceutical and Biopharmaceutical Companies play a crucial role in utilizing Patient-Derived Xenograft models for drug development, enabling more precise testing of therapies, thereby driving innovations in treatment options.
Academic and Research Institutes significantly contribute to the market by providing foundational research and insights that enhance the understanding of cancer biology and therapeutic responses, supporting advancements in personalized medicine.CROs are vital as they offer outsourced research services, facilitating the efficient execution of clinical trials and enhancing the speed at which new drugs come to market. CDMOs also hold importance, as they manage the complex process of drug manufacturing, with Patient-Derived Xenograft models serving as integral tools for process validation and quality control in biopharmaceutical productions.
Collectively, these entities form a dynamic ecosystem that is pivotal for the growth of the Patient-Derived Xenograft Model Market in China, where there is a notable push towards advanced cancer research and novel therapeutic strategies.
The China Patient-Derived Xenograft Model Market is characterized by its dynamic and rapidly evolving nature, reflecting a growing demand for advanced research models that closely mimic human tumors. This market is being shaped by several strategic competitors who strive to enhance innovation, improve customer offerings, and expand their service capabilities. Competitive insights reveal that companies are focusing heavily on partnerships, collaborations, and investment in research to develop more efficient and reliable xenograft models.
With a rise in personalized medicine and a robust increase in cancer research, the market is witnessing a surge in activity, which is fostering a race among companies to establish their presence and gain a competitive advantage.Crown Bioscience is a prominent player in the China Patient-Derived Xenograft Model Market and is recognized for its extensive portfolio of patient-derived xenograft models that facilitate cancer research and drug development.
The company’s strengths lie in its robust capability to provide high-quality and reliable biological models that are vital for preclinical studies. Crown Bioscience boasts a wide range of models that represent diverse tumor types, which contribute effectively to accelerating drug discovery processes. By leveraging its comprehensive understanding of tumor biology and strong technical expertise, Crown Bioscience has positioned itself as a key provider in the market, catering to the increasing needs of research institutions and biopharmaceutical companies.
Thermo Fisher Scientific plays a significant role in the China Patient-Derived Xenograft Model Market, distinguished by its commitment to offering comprehensive solutions that support cancer research and therapeutic development. The company's strength lies in its extensive range of services and products specifically tailored for in vivo modeling, including patient-derived xenograft models that meet the stringent requirements of researchers in China. Thermo Fisher Scientific actively seeks to enhance its market presence through strategic partnerships and collaborations aimed at expanding its product offerings.
The company has also pursued key mergers and acquisitions to bolster its capabilities, thus enabling it to provide advanced solutions that streamline the research process. Its cutting-edge technologies and commitment to quality further solidify its position in this competitive landscape, ensuring it remains an essential resource for scientists in the region focused on breakthroughs in cancer treatment.
In recent months, the China Patient-Derived Xenograft Model Market has experienced significant activity, particularly with key players such as Crown Bioscience, Thermo Fisher Scientific, and Charles River Laboratories. Notably, in July 2023, Crown Bioscience announced an expansion of its capabilities in China, enhancing its offering of preclinical services aimed at improving drug discovery processes. Meanwhile, Thermo Fisher Scientific has been increasing its investment in Research and Development in the region to bolster its presence in the oncology market.
In terms of mergers and acquisitions, Jinshan Science & Technology has been in discussions for a potential partnership with a leading biotech firm focused on immuno-oncology solutions, indicative of a trend towards consolidating resources to leverage advanced therapies. Furthermore, the market valuation has shown growth, largely driven by increasing demand for personalized medicine, with projections indicating a compound annual growth rate of approximately 15% for the next five years. Regulatory approvals from governing bodies in China have also streamlined the process for bringing new xenograft models to market, thereby promoting innovation and competitive dynamics. In the broader context, the focus on patient-specific therapies has garnered governmental support, enhancing collaboration within the industry.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 19.77(USD Million) |
| MARKET SIZE 2024 | 22.4(USD Million) |
| MARKET SIZE 2035 | 87.24(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 13.156% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | Crown Bioscience, Thermo Fisher Scientific, OncoOne, Jinshan Science & Technology, Charles River Laboratories, Harvard Bioscience, In vivo Therapeutics, Genentech, Genocea Biosciences, H2O Innovation |
| SEGMENTS COVERED | Tumor Type, Model Type, End-User |
| KEY MARKET OPPORTUNITIES | Rising cancer research funding, Increasing demand for personalized medicine, Expanding pharmaceutical R&D investments, Growth in preclinical testing services, Advancements in genomic technologies |
| KEY MARKET DYNAMICS | Rising cancer research funding, Increasing demand for personalized medicine, Technological advancements in xenograft models, Growing focus on drug efficacy testing, Expanding biopharmaceutical industry partnerships |
| COUNTRIES COVERED | China |
Frequently Asked Questions (FAQ) :
The market is expected to be valued at 87.24 million USD by 2035.
In 2024, the market is valued at 22.4 million USD.
The expected CAGR for the market is 13.156 percent from 2025 to 2035.
Lung cancer holds the largest market share valued at 6.72 million USD in 2024.
Major players include Crown Bioscience, Thermo Fisher Scientific, and Charles River Laboratories.
The market value for pancreatic cancer in 2024 is 4.48 million USD.
The market for breast cancer is expected to reach 21.43 million USD by 2035.
Emerging regulations and competition from alternative models may challenge market growth.
The market size for prostate cancer is projected to be 14.75 million USD in 2035.
Growth rates vary, with lung cancer showing significant demand and expansion during this period.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Analyst Explore the profile of garvit vyas, one of our esteemed authors at market research future, and access their expert research contributions in the field of market research and industry analysis
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
